Global Life Sciences Solutions Operations UK Ltd, trading as Cytiva, is a leading provider of advanced technologies and services that accelerate the development and manufacture of therapeutics. Tracing its roots back hundreds of years, Cytiva operates globally and is part of Danaher Corporation since 2020. Their primary focus is supplying innovative tools and services to clients engaged in life-saving research—spanning drug development, biological research, cell and gene therapies, and innovative vaccines.
Cytiva’s comprehensive portfolio serves diverse customers engaged in fundamental biology through to the delivery of transformative medicines. By supporting both start-ups and major biopharma companies, Cytiva’s mission is to enhance the efficiency, speed, and safety of research and manufacturing workflows to improve patient outcomes worldwide. Operating in over 40 countries and employing more than 7,000 associates, Cytiva has a prominent presence in the United Kingdom and across Europe, Asia, the Americas, and the Middle East.
Cytiva’s engagement with EU policy primarily involves contributing to legislative and regulatory discussions that relate to industrial policy, trade, European healthcare, pharmaceuticals, intellectual property, environment, life sciences skills, and other domains crucial to health innovation. Since its first EU Transparency Registration on April 12, 2021, Cytiva has positioned itself as a key interest group promoting both its own and its sector’s priorities, focused on enhancing the environment for life sciences innovation and manufacturing in the EU context. This proactive engagement is complemented by involvement in significant trade and business associations such as MedTech Europe and EuropaBio. Cytiva does not have directly accredited lobbyists to the European Parliament, but it employs a small, specialized team for its lobbying functions, supplemented by mandating intermediaries for specific projects.
The firm’s financial and lobbying activity disclosures indicate a targeted approach, with declared expenditure within the range stipulated by EU requirements and transparent reporting through the EU register. Cytiva’s lobbying activity encompasses a range of topics like regulatory policies, sustainability, pandemic preparedness, and supply chain resilience, shaped by the rapidly evolving healthcare and bioscience landscape. Through its sustained presence, Cytiva plays a constructive role in shaping EU policies, working with various stakeholders to foster a regulatory environment supportive of health technology and access to transformative therapies
